6th December 2019 – The global Epilepsy
Drugs Market is anticipated to rise at a staggering CAGR in the
forthcoming period. Epilepsy drugs have pharmacokinetic properties and are
administered to children, adults, and adolescents. Carbamazepine is applicable
for focal seizures with strong properties of inducing and enables development
of milder tolerance level that could be increased weekly.
Epilepsy drugs market is highly driven
by rise in cases of stroke, brain tumors, and brain injury. Antiepileptic drugs
are prescribed due to the rising demands for treatment for epilepsy. Adoption
of novel approach by manufacturers for production of therapeutic drugs also
contributes to the market growth in the forecast period.
Change in lifestyle and increase in
geriatric population with unmet medical needs along with rise in awareness is
expected to trigger the market growth in the near future. However, rise in
demand for generic drugs and availability of cheaper substitutes are likely to
hinder the market growth in the forecast period.
Get
a Sample Copy of This Report @ https://www.millioninsights.com/industry-reports/epilepsy-drugs-market/request-sample
On the basis of generation, the epilepsy
drugs market is segmented as first generation epileptic drugs, second
generation epileptic drugs, and pipeline drugs. Pipeline drugs hold a
significant market share in the forecast period due to their enhanced
efficiency and efficacy.
Geographical segmentation for epilepsy
drugs industry includes North America, South America, Europe, Asia-Pacific,
Middle East and Africa. North America is a huge market exhibiting higher
potential in terms of diagnosis and treatments coupled with rise in prevalence
of epilepsy since it has affected a major population in the United States.
Asia-Pacific regions have also
registered a remarkable growth in the forecast period due to high prevalence of
epilepsy in several parts of the region. Availability of drugs and treatment
through novel mechanisms are some factors driving the market growth for APAC.
Latin America is a huge market for epilepsy drugs that encompasses significant
healthcare expenditure along with higher prevalence of epileptic cases in the
region. The key players in the epilepsy drugs market include Sanofi S.A., UCB
Pharma Ltd, Valeant Pharmaceuticals, Pfizer Inc, Johnson & Johnson Co,
Abbott Laboratories Inc, Novartis AG, GlaxoSmithKline PLC, CephalonInc, and
SunovionPharamceuticals.
Get
in touch
At Million Insights, we work with the
aim to reach the highest levels of customer satisfaction. Our representatives
strive to understand diverse client requirements and cater to the same with the
most innovative and functional solutions.
For
More Information, Visit @ https://www.millioninsights.com
No comments:
Post a Comment